213 related articles for article (PubMed ID: 24243883)
21. Enhancement of immune responses by co-administration of bacterial ghosts-mediated Neisseria gonorrhoeae DNA vaccines.
Jiao H; Yang H; Zheng W; Zhang Q; Zhao D; Li G
J Appl Microbiol; 2021 May; 130(5):1770-1777. PubMed ID: 32770820
[TBL] [Abstract][Full Text] [Related]
22. Female Mouse Model of Neisseria gonorrhoeae Infection.
Raterman EL; Jerse AE
Methods Mol Biol; 2019; 1997():413-429. PubMed ID: 31119637
[TBL] [Abstract][Full Text] [Related]
23. Isolation of Naturally Released Gonococcal Outer Membrane Vesicles as Vaccine Antigens.
Francis IP; Lui X; Wetzler LM
Methods Mol Biol; 2019; 1997():121-141. PubMed ID: 31119622
[TBL] [Abstract][Full Text] [Related]
24. Design and immune characterization of a novel Neisseria gonorrhoeae DNA vaccine using bacterial ghosts as vector and adjuvant.
Jiao H; Yang H; Zhao D; Chen J; Zhang Q; Liang J; Yin Y; Kong G; Li G
Vaccine; 2018 Jul; 36(30):4532-4539. PubMed ID: 29914847
[TBL] [Abstract][Full Text] [Related]
25. Human experimentation with Neisseria gonorrhoeae: progress and goals.
Cohen MS; Cannon JG
J Infect Dis; 1999 Mar; 179 Suppl 2():S375-9. PubMed ID: 10081510
[TBL] [Abstract][Full Text] [Related]
26. The potential impact of vaccination on the prevalence of gonorrhea.
Craig AP; Gray RT; Edwards JL; Apicella MA; Jennings MP; Wilson DP; Seib KL
Vaccine; 2015 Aug; 33(36):4520-4525. PubMed ID: 26192351
[TBL] [Abstract][Full Text] [Related]
27. Mucosal immunity in the genital tract: prospects for vaccines against sexually transmitted diseases--a review.
Russell MW; Hedges SR; Wu HY; Hook EW; Mestecky J
Am J Reprod Immunol; 1999 Jul; 42(1):58-63. PubMed ID: 10429768
[TBL] [Abstract][Full Text] [Related]
28. Targeting Lipooligosaccharide (LOS) for a Gonococcal Vaccine.
Gulati S; Shaughnessy J; Ram S; Rice PA
Front Immunol; 2019; 10():321. PubMed ID: 30873172
[TBL] [Abstract][Full Text] [Related]
29. [Ways and prospects of producing gonococcal vaccine].
Bednova VN; Dmitriev GA; Pasternak NI
Vestn Dermatol Venerol; 1987; (11):41-7. PubMed ID: 3125694
[No Abstract] [Full Text] [Related]
30. Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-β-dependent mechanisms.
Liu Y; Islam EA; Jarvis GA; Gray-Owen SD; Russell MW
Mucosal Immunol; 2012 May; 5(3):320-31. PubMed ID: 22354319
[TBL] [Abstract][Full Text] [Related]
31. MetQ of Neisseria gonorrhoeae Is a Surface-Expressed Antigen That Elicits Bactericidal and Functional Blocking Antibodies.
Semchenko EA; Day CJ; Seib KL
Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27895130
[TBL] [Abstract][Full Text] [Related]
32. Summary and Recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) Workshop "Gonorrhea Vaccines: the Way Forward".
Wetzler LM; Feavers IM; Gray-Owen SD; Jerse AE; Rice PA; Deal CD
Clin Vaccine Immunol; 2016 Aug; 23(8):656-63. PubMed ID: 27335384
[TBL] [Abstract][Full Text] [Related]
33. Neisseria gonorrhoeae: a versatile pathogen.
Easmon CS; Ison CA
J Clin Pathol; 1987 Sep; 40(9):1088-97. PubMed ID: 3117850
[TBL] [Abstract][Full Text] [Related]
34. In-silico Hierarchical Approach for the Identification of Potential Universal Vaccine Candidates (PUVCs) from Neisseria gonorrhoeae.
Jain R; Sonkar SC; Chaudhry U; Bala M; Saluja D
J Theor Biol; 2016 Dec; 410():36-43. PubMed ID: 27596531
[TBL] [Abstract][Full Text] [Related]
35. Preliminary studies on the development of a gonococcal vaccine.
Greenberg I; Diena BB; Kenny CP; Znamirowski R
Bull World Health Organ; 1971; 45(4):531-5. PubMed ID: 5004708
[No Abstract] [Full Text] [Related]
36. The threat of untreatable gonorrhoea: implications and consequences for reproductive and sexual morbidity.
Ndowa F; Lusti-Narasimhan M
Reprod Health Matters; 2012 Dec; 20(40):76-82. PubMed ID: 23245412
[TBL] [Abstract][Full Text] [Related]
37. Strategies for mimicking Neisserial saccharide epitopes as vaccines.
Gulati S; Ngampasutadol J; Yamasaki R; McQuillen DP; Rice PA
Int Rev Immunol; 2001; 20(2):229-50. PubMed ID: 11878767
[TBL] [Abstract][Full Text] [Related]
38. Proteomics-driven Antigen Discovery for Development of Vaccines Against Gonorrhea.
Zielke RA; Wierzbicki IH; Baarda BI; Gafken PR; Soge OO; Holmes KK; Jerse AE; Unemo M; Sikora AE
Mol Cell Proteomics; 2016 Jul; 15(7):2338-55. PubMed ID: 27141096
[TBL] [Abstract][Full Text] [Related]
39. A vaccine against gonorrhoea?
Br Med J; 1977 Oct; 2(6092):917-8. PubMed ID: 410476
[No Abstract] [Full Text] [Related]
40. Vaccines for gonorrhea: where are we on the curve?
Blake MS; Wetzler LM
Trends Microbiol; 1995 Dec; 3(12):469-74. PubMed ID: 8800838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
